EGFR and non-small cell lung carcinoma: Case studies show that NSCLC patients with EGFR-KDD can have durable partial response to either first-line [106] or second-line treatment with gefitinib [109], though at least one patient with EGFR-KDD did to respond to first-line gefitinib [106].